Cameron
Lv7
4990 积分
2022-07-17 加入
-
A phase 1, first-in-human study of AMT-676, an anti-CDH17 antibody-drug conjugate, in patients with advanced gastrointestinal tumors
2天前
求助中
-
Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial
7天前
已完结
-
Backfilling cohorts in phase I dose-escalation studies
1个月前
已完结
-
Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study
3个月前
已完结
-
Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study
3个月前
已完结
-
Sex differences in the evolution of the electrocardiographic QT interval with age
3个月前
已关闭
-
Claudin 18.2-targeting antibody–drug conjugate CMG901 in patients with advanced gastric or gastro-oesophageal junction cancer (KYM901): a multicentre, open-label, single-arm, phase 1 trial
3个月前
已完结
-
Claudin 18.2-targeting antibody–drug conjugate CMG901 in patients with advanced gastric or gastro-oesophageal junction cancer (KYM901): a multicentre, open-label, single-arm, phase 1 trial
3个月前
已完结
-
Nivolumab plus Ipilimumab in Microsatellite-Instability–High Metastatic Colorectal Cancer
3个月前
已完结
-
Zongertinib in Previously Treated HER2 -Mutant Non–Small-Cell Lung Cancer
3个月前
已完结